Science
CCR Score Could Offer ADT-Free Path in Higher-Risk Prostate Cancer – MedPage Today
Large proportion of intermediate- to high-risk patients could avoid aggressive therapy
A prognostic risk estimator that incorporates genomic data and clinical factors could allow for the elimination of androgen deprivation therapy (ADT) in some men with intermediate- or high-risk prostate cancer following radiation therapy (RT), a researcher reported.
In a retrospective validation study involving nearly 750 men who received dose-escalated RT, those with a combined clinical cell-cycle risk (CCR) score below a cutoff of 2.112 had a 10-year risk of distant metastasis of just 4.1%, regardless…
-
Business15 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?
-
General22 hours agoRussia launches hundreds of drones and missiles against Ukraine in fresh attack
-
Business14 hours agoHere’s what analysts expect for the BHP share price in the coming year
-
Business17 hours agoOwn Xero shares? Here are 3 key takeaways from its AGM